u/ewan_marchand

stretching the interval is not the same as reducing the dose

if it matters, ask somebody qualified in your own jurisdiction

That service reports area percent by default. Worth stating, since the thread has been comparing it to a mass figure.

the TRIUMPH programme is still running, so anything definitive is premature

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

removals get explained publicly where the rule allows it

How old is the column and roughly how many injections has it seen?

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

That reading assumes area percent and net peptide content are the same number. They are not, and the report says which it is.

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

do not chase the last two kilos with a dose increase

Yes — interval stretching and dose reduction are different levers and people use the words interchangeably.

Gave the same trace to two people I trust and got two integrations about a point apart. That was the most educational afternoon I have had here.

Agreed — and two services on one batch is the strongest thing any of us can produce individually.

stubborn_batchlist_only is right that the band matters more than the peak. Consistency across lots is the finding.

Left up.

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

Clearance took four days and the carrier took eleven. I had been blaming entirely the wrong stage for a year.

reproducibility beats resolution if you only get one of them

What did system suitability look like on that sequence?

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Sent the same vial to Medutest and Janoshik.

Agreed. And the corollary is that the method line on a certificate is not decoration, it is the number’s provenance.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Fourth lot from the same supplier in the log now and the band has been tight the whole way. That consistency is the actual finding.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

Correction: TRIUMPH is the phase 3 programme.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

heart rate is the thing people report watching

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Left up.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

a lot of people plateau nicely at 10mg and never need 15

nothing here is available as a prescription product, so read every thread with that in mind

a lot of the confident posting here is extrapolation

Is that baseline drawn by the software or by hand?

Stretching the interval, reducing the dose, or both?

research-use-only material is not approved for human use, full stop

Yes — date of analysis, because a result from two years ago describes a different manufacturing month.

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

What was the claim on the certificate you are comparing against?